Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

M. Marre, J. Shaw, M. Brandle, W. M. W. Bebakar, N. A. Kamaruddin, J. Strand, M. Zdravkovic, T. D. Le Thi and S. Colagiuri

Diabetic Medicine 26 ( 3 ): 268 - 278 , 2009